FTSE 100 stocks to buy and hold until 2030

Rupert Hargreaves highlights four FTSE 100 stocks that he’d buy and hold until 2030, considering their growth prospects.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Finding stocks to buy and hold for the next decade is incredibly challenging. Indeed, there’s no road map or shortcut I can use to find FTSE 100 stocks that’ll be around 10 years from now. 

However, by focusing on well-run companies with a sustainable competitive advantage, I think I can improve my chances of finding a long term buy-and-forget forget investment. 

There are a handful of companies in the FTSE 100 that appear as if they have these qualities. I’d buy all of them for that reason. 

FTSE 100 stocks to buy 

A great place to start looking for companies with a sustainable competitive advantage is the pharmaceutical sector. When drugs companies develop a treatment, they’re protected by exclusive manufacturing rights for an extended period. This is their primary competitive advantage. The companies can effectively charge what they like for these products while they’ve exclusive manufacturing rights. 

I think AstraZeneca is one of the most exciting pharmaceutical companies listed on the London market. It has been spending billions developing cancer treatments, and these treatments are now becoming a significant revenue stream for the group. 

Unfortunately, exclusive manufacturing rights don’t last forever. When they come to an end, companies like Hikma can produce the same product at a lower cost. That’s why I would buy both Astra and Hikma.

While Astra has a great portfolio of exclusive treatments, Hikma’s one of the world’s largest producers of generic drugs. Its competitive advantage is its size. It can produce these drugs at a much lower cost than competitors. As the global healthcare sector grows, I think the demand for these services will only expand. 

Both of these companies also have significant pricing power, but they could come under pressure from regulators to lower costs. If they do, this is one of the biggest challenges they may have to overcome. 

Long-term outlook

As well as the pharmaceutical companies outlined above, I’d also by Legal & General to hold in my portfolio FTSE 100 stocks.

This company is built for the long term. Its primary lines of business are pension and life insurance. In both of these markets, the group has to have a multi-generation perspective. Consumers buying life insurance and pension products need to be sure the organisation will still be around when they come to use them.

As such, management has to make decisions with long-term success in mind. This is a fantastic quality for a buy-and-forget investment, in my opinion. 

I’d also require distribution group Bunzl. Investors should never use past performance to guide future potential, but this company has successfully grown to become one of the UK’s largest corporations over the past few decades. 

Through a combination of acquisitions and organic growth, the enterprise has gone from strength to strength. It’s now a force to be reckoned with in the relatively uninteresting distribution industry. Management has no plans to change its strategy anytime soon. That’s why I think the company can continue to grow for the next decade. 

Unfortunately, while both of these businesses may be doing everything in their power to build a solid organisation, there’s always going to be the chance a hidden risk will emerge. This could hurt growth, or even lead to asset sales.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves has no position in any of the shares mentioned. The Motley Fool UK has recommended Bunzl and Hikma Pharmaceuticals. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Young Caucasian woman with pink her studying from her laptop screen
Dividend Shares

These 2 dividend stocks are getting way too cheap

Jon Smith looks at different financial metrics to prove that some dividend stocks are undervalued at the moment and could…

Read more »

Investing Articles

Is the JD Sports share price set to explode?

Christopher Ruane considers why the JD Sports share price has done little over the past five years, even though sales…

Read more »

Middle-aged black male working at home desk
Investing Articles

The Anglo American share price dips on Q1 production update. Time to buy?

The Anglo American share price has fallen hard in the past two years, after a very tough 2023. But I…

Read more »

Young Asian man drinking coffee at home and looking at his phone
Investing Articles

£9,000 in savings? Here’s how I’d aim to turn that into a £12,300 annual passive income

This Fool explains how he'd target thousands of pounds in passive income every year by investing in high-quality businesses.

Read more »

Market Movers

Why is the FTSE 100 at all-time highs?

Jon Smith flags up two reasons for the jump in the FTSE 100 over the past week, also pointing out…

Read more »

A couple celebrating moving in to a new home
Investing Articles

The Taylor Wimpey share price rises on housing market ‘stability’. Time to consider buying?

The 2024 Taylor Wimpey share price hasn't been in great form, so far. But Paul Summers remains cautiously optimistic for…

Read more »

Investor looking at stock graph on a tablet with their finger hovering over the Buy button
Investing Articles

The FTSE 100 reaches an all-time high! Here are 2 of its best stocks to consider buying

With the FTSE 100 soaring in 2024, this Fool thinks investors should consider buying these two stocks. Here he breaks…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Here’s why I see cheap UK shares soaring in the years ahead

UK shares look undervalued and this Fool plans to take advantage of it. Here he details one stock he's keen…

Read more »